慢性心力衰竭:FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格

2019-06-27 Allan MedSci原创

礼来和勃林格殷格翰近日表示,FDA已授予Jardiance(empagliflozin)快速通道资格用于降低慢性心力衰竭患者心血管死亡和心力衰竭住院的风险。

礼来和勃林格殷格翰近日表示,FDA已授予Jardianceempagliflozin)快速通道资格用于降低慢性心力衰竭患者心血管死亡和心力衰竭住院的风险。该公司称,该指定适用于正在进行的EMPEROR计划,其中包括EMPEROR-ReducedEMPEROR-Preserved研究,评估每日一次SGLT2抑制剂对慢性心力衰竭患者心血管死亡和心力衰竭住院治疗的影响。

勃林格殷格翰的临床开发和医疗事务副总裁Mohamed Eid表示,心力衰竭导致九分之一的死亡,并且是美国住院治疗的主要原因,但治疗选择有限。他补充说,Jardiance的快速通道指定是解决这一未满足需求的重要一步


原始出处:

http://www.firstwordpharma.com/node/1649699#axzz5s0nRyue8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2020-03-22 tulenzi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-08-05 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-06-29 jiekemin
  9. [GetPortalCommentsPageByObjectIdResponse(id=1793825, encodeId=10111e938255a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sun Mar 22 17:35:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852042, encodeId=491118520425e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 05 12:35:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Aug 13 20:35:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639156, encodeId=d4c91639156fa, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Feb 22 03:35:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251804, encodeId=1820125180477, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33419, encryptionId=16c6334194b, topicName=勃林格殷格翰)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hjvBw7A63jJ2K2g8r4xGicDySjxRg0VLfNGLRpAGlkLtrrP7DcsN36rGPeuquA7llSUAU1jac7ETpMYnaAZxvvA/132, createdBy=7ae75331052, createdName=ymljack, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495271, encodeId=f52514952e176, content=<a href='/topic/show?id=9b035208633' target=_blank style='color:#2F92EE;'>#快速通道资格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52086, encryptionId=9b035208633, topicName=快速通道资格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf79160797, createdName=Eleven14, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503784, encodeId=30c51503e8423, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585514, encodeId=4f3715855144f, content=<a href='/topic/show?id=0d151025305' target=_blank style='color:#2F92EE;'>#Jardiance#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10253, encryptionId=0d151025305, topicName=Jardiance)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=065617213305, createdName=lq1773, createdTime=Sat Jun 29 01:35:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-06-29 lq1773

相关资讯

FDA发出安全警告:2型糖尿病药物SGLT2抑制剂与严重的生殖器感染存在相关性

FDA发出警告称:SGLT2抑制剂,包括阿斯利康的Farxiga(dapagliflozin)和礼来的Jardiance(empagliflozin),与会阴坏死性筋膜炎(又称为阴囊坏疽)的疾病具有相关性。FDA表示需要在所有SGLT2抑制剂的处方信息中添加关于此风险的新警告。

III期临床试验证实,强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

强生公司宣布了其Invokana(canagliflozin)III期临床试验的结果,证明该药可将II型糖尿病(T2DM)和慢性肾病患者肾功能衰竭、透析或肾移植以及肾脏或心血管死亡的风险降低30%。

JCEM:SGLT2抑制剂增加了糖尿病酮症酸中毒的风险

由此可见,与非SGLT2i服用者相比,住院的SGLT2i服用者更有可能发生DKA。SGLT2i的使用与DKA的风险显著增加相关。

2019 ADA:阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病

阿斯利康(AZ)在美国糖尿病协会大会(ADA)上发表的数据显示其SGLT2抑制剂Farxiga(达格列嗪)可以预防2型糖尿病的并发症,并减轻肾脏疾病的进展。

Diabetes Obes Metab:与SGLT2抑制剂相关的生殖器感染风险分析

由此可见,风险在治疗开始的第一个月内显而易见,并且在整个治疗过程中仍然保持升高。SGLT2抑制剂会导致生殖器感染风险增加约三倍。

BMJ:钠葡萄糖协同转运蛋白2抑制剂和严重不良事件的风险

由此可见,在对来自两个国家的全国性登记的分析中,与GLP1受体激动剂相比,使用SGLT2抑制剂与下肢截肢和糖尿病酮症酸中毒的风险增加相关,但与当前关注的其它严重不良事件无关。